Uganda has launched a clinical trial for a promising Ebola vaccine targeting the Sudan strain of the virus, marking a significant step forward in strengthening the country’s ability to combat outbreaks.

The trial, which prioritizes frontline health workers and individuals at risk of exposure, aims to assess the effectiveness of a vaccine developed by the International AIDS Vaccine Initiative (IAVI), a global non-profit organization. The first participant, currently under observation, has already received a dose, signaling the start of this crucial study.

The World Health Organization (WHO) has allocated $1 million from its Contingency Fund for Emergencies to support Uganda's rapid response. Health authorities emphasize preventive measures and public awareness to curb the spread, urging citizens to remain vigilant and avoid direct contact with suspected Ebola cases.

This marks Uganda’s eighth Ebola outbreak since 2000, with the last one successfully contained in early 2023. With this vaccine trial, the country is taking proactive steps toward long-term protection against future outbreaks, reinforcing its commitment to public health and global disease prevention efforts.